Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
The FDA has granted accelerated approval to Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers.
Healthtech
EMA launches ESMP for better management of drug shortages in EU
Reeves’ 2024 budget promises life sciences investment
Gene therapy: How Veristat cut trial database costs by 30%
Anti-obesity drugs will be 2024’s defining trend
Untapped opportunities: Fulfilling the promise of decentralized clinical trials
Signal: Lilly searches for new obesity drugs in partnership with Fauna Bio
Precision and personalized medicine: the leading companies in personalized cancer vaccines revealed
